Keller Sara C, Dzintars Kathryn, Gorski Lisa A, Williams Deborah, Cosgrove Sara E
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Pharmacy, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pharmacotherapy. 2018 Apr;38(4):476-481. doi: 10.1002/phar.2099. Epub 2018 Mar 30.
Debate about whether certain antimicrobial agents traditionally considered vesicants increase the risk of catheter complications has led to uncertainty in venous catheter placement protocols. To understand whether patients requiring home-based outpatient parenteral antimicrobial therapy (OPAT) should receive peripheral catheters (e.g., midline catheters) versus central venous catheters, and to understand whether certain antimicrobial agents place home-based OPAT patients at higher risk for catheter complications, we investigated associations between antimicrobial agent(s) and catheter complications.
We performed a prospective cohort study of patients requiring home-based OPAT discharged from two urban tertiary care academic medical centers, including telephone surveys and chart abstractions. Multivariable Poisson regressions were used to evaluate: (i) associations between antimicrobial agents traditionally considered vesicants, based on pH or osmolarity, and catheter complication rates, and (ii) associations between antimicrobial agent and rates of catheter complications.
Vesicant antimicrobials defined using pH or osmolarity criteria were not associated with an increased rate of catheter complications (adjusted incidence rate ratio [aIRR]: 1.63, 95% confidence interval [CI]: 0.89-2.96). Vancomycin was associated with an increased rate of catheter complications, as was daptomycin (aIRR: 2.32 [95% CI: 1.20-4.46] and 4.45 [95% CI: 1.02-19.41], respectively). Staphylococcus aureus infections were also associated with an increased rate of catheter complications (aIRR: 2.13, 95% CI: 1.09-4.19), as were midline catheters (aIRR: 9.44, 95% CI: 2.12-41.97).
Our study supports recent guidance identifying vancomycin as a vesicant, among a subset of antimicrobial agents, and removal of pH criteria for identification of vesicants.
关于某些传统上被认为是发泡剂的抗菌药物是否会增加导管并发症风险的争论,导致了静脉导管置入方案的不确定性。为了了解需要居家门诊胃肠外抗菌治疗(OPAT)的患者应接受外周导管(如中线导管)还是中心静脉导管,以及某些抗菌药物是否会使居家OPAT患者发生导管并发症的风险更高,我们调查了抗菌药物与导管并发症之间的关联。
我们对两家城市三级医疗学术医学中心出院的需要居家OPAT的患者进行了一项前瞻性队列研究,包括电话调查和病历摘要。多变量泊松回归用于评估:(i)基于pH值或渗透压传统上被认为是发泡剂的抗菌药物与导管并发症发生率之间的关联,以及(ii)抗菌药物与导管并发症发生率之间的关联。
使用pH值或渗透压标准定义的发泡性抗菌药物与导管并发症发生率增加无关(调整后的发病率比[aIRR]:1.63,95%置信区间[CI]:0.89 - 2.96)。万古霉素与导管并发症发生率增加有关,达托霉素也是如此(aIRR分别为:2.32 [95% CI:1.20 - 4.46]和4.45 [95% CI:1.02 - 19.41])。金黄色葡萄球菌感染也与导管并发症发生率增加有关(aIRR:2.13,95% CI:1.09 - 4.